137 related articles for article (PubMed ID: 35700113)
1. Effects of direct-acting antiviral agents on lipid and glucose profile in HCV patients with type 2 diabetes: A real-life Italian experience.
Dalbeni A; Villani R; Bevilacqua M; Sacco F; Faccincani D; Cattazzo F; Cavallone F; Mantovani A; Ceruti V; Ieluzzi D; Paon V; Mantovani A; Serviddio G; Sacerdoti D
J Dig Dis; 2022 May; 23(5-6):324-330. PubMed ID: 35700113
[TBL] [Abstract][Full Text] [Related]
2. Hepatitis C virus eradication by direct-acting antiviral agents improves carotid atherosclerosis in patients with severe liver fibrosis.
Petta S; Adinolfi LE; Fracanzani AL; Rini F; Caldarella R; Calvaruso V; Cammà C; Ciaccio M; Di Marco V; Grimaudo S; Licata A; Marrone A; Nevola R; Pipitone RM; Pinto A; Rinaldi L; Torres D; Tuttolomondo A; Valenti L; Fargion S; Craxì A
J Hepatol; 2018 Jul; 69(1):18-24. PubMed ID: 29505844
[TBL] [Abstract][Full Text] [Related]
3. Hepatitis C Virus Eradication with New Interferon-Free Treatment Improves Metabolic Profile in Hepatitis C Virus-Related Liver Transplant Recipients.
Beig J; Orr D; Harrison B; Gane E
Liver Transpl; 2018 Aug; 24(8):1031-1039. PubMed ID: 29577581
[TBL] [Abstract][Full Text] [Related]
4. Sustained virological response by direct antiviral agents in HCV leads to an early and significant improvement of liver fibrosis.
Persico M; Rosato V; Aglitti A; Precone D; Corrado M; De Luna A; Morisco F; Camera S; Federico A; Dallio M; Claar E; Caporaso N; Masarone M
Antivir Ther; 2018; 23(2):129-138. PubMed ID: 28799522
[TBL] [Abstract][Full Text] [Related]
5. Over time evaluation of glycaemic control in direct-acting antiviral-treated hepatitis C virus/diabetic individuals with chronic hepatitis or with cirrhosis.
Cacciola I; Russo G; Filomia R; Pitrone C; Caccamo G; Giandalia A; Alibrandi A; Stella Franzè M; Porcari S; Maimone S; Saitta C; Squadrito G; Raimondo G
Liver Int; 2021 Sep; 41(9):2059-2067. PubMed ID: 33894103
[TBL] [Abstract][Full Text] [Related]
6. Effects of HCV Clearance with Direct-Acting Antivirals (DAAs) on Liver Stiffness, Liver Fibrosis Stage and Metabolic/Cellular Parameters.
Ferreira J; Bicho M; Serejo F
Viruses; 2024 Feb; 16(3):. PubMed ID: 38543737
[TBL] [Abstract][Full Text] [Related]
7. Metabolic, renal, and hematological changes in chronic hepatitis C patients achieving rapid virologic response after 12 weeks of direct-acting antiviral treatment: A prospective cohort study.
Thi Thu PN; Hoang Van D; Ngo Thi Quynh M; Tran Thi N; Pham Minh K; Pham Van L
PLoS One; 2023; 18(9):e0290235. PubMed ID: 37656689
[TBL] [Abstract][Full Text] [Related]
8. Modification of liver fibrosis, glucose and lipid profile after hepatitis C virus clearance with direct-acting antiviral agents.
Goñi Esarte S; Juanbeltz R; Zozaya JM; Úriz JI; Castilla J; Herrero JI
Gastroenterol Hepatol; 2020 May; 43(5):248-255. PubMed ID: 32192765
[TBL] [Abstract][Full Text] [Related]
9. Virus Elimination by Direct-Acting Antiviral Agents Impacts Glucose Homeostasis in Chronic Hepatitis C Patients.
Cheng CH; Chu CY; Chen HL; Lin IT; Wu CH; Lee YK; Bair MJ
Front Endocrinol (Lausanne); 2021; 12():799382. PubMed ID: 35095765
[TBL] [Abstract][Full Text] [Related]
10. Reduced incidence of type 2 diabetes in patients with chronic hepatitis C virus infection cleared by direct-acting antiviral therapy: A prospective study.
Adinolfi LE; Petta S; Fracanzani AL; Nevola R; Coppola C; Narciso V; Rinaldi L; Calvaruso V; Pafundi PC; Lombardi R; Staiano L; Di Marco V; Solano A; Marrone A; Saturnino M; Rini F; Guerrera B; Troina G; Giordano M; Craxì A; Sasso FC
Diabetes Obes Metab; 2020 Dec; 22(12):2408-2416. PubMed ID: 32761721
[TBL] [Abstract][Full Text] [Related]
11. Direct-acting antiviral agents decrease haemoglobin A1c level in patients with diabetes infected with hepatitis C virus: A systematic review & meta-analysis.
Lapumnuaypol K; Pisarcik D; Putthapiban P; Sukhumthammarat W; Wijarnpreecha K; Thongprayoon C; Ungprasert P
Indian J Med Res; 2020 Dec; 152(6):562-567. PubMed ID: 34145095
[TBL] [Abstract][Full Text] [Related]
12. Impact of Direct-Acting Antiviral Therapy on Liver Fibrosis Regression among People with Chronic HCV Infection: Results from a Real-Life Cohort in Patients Who Achieved Sustained Virological Response.
García-Ros A; Morán S; Núñez V; García-Ros G; Ruiz G; García-Solano J
Medicina (Kaunas); 2023 Apr; 59(4):. PubMed ID: 37109770
[No Abstract] [Full Text] [Related]
13. DAA therapy and long-term hepatic function in advanced/decompensated cirrhosis: Real-world experience from HCV-TARGET cohort.
Verna EC; Morelli G; Terrault NA; Lok AS; Lim JK; Di Bisceglie AM; Zeuzem S; Landis CS; Kwo P; Hassan M; Manns MP; Vainorius M; Akushevich L; Nelson DR; Fried MW; Reddy KR
J Hepatol; 2020 Sep; 73(3):540-548. PubMed ID: 32243960
[TBL] [Abstract][Full Text] [Related]
14. Effect of direct acting antiviral therapy of Chronic Hepatitis C virus on insulin resistance and Type2 DM in Egyptian patients (prospective study).
Boraie MB; Elnaggar YA; Ahmed MO; Mahmoud AM
Diabetes Metab Syndr; 2019; 13(4):2641-2646. PubMed ID: 31405688
[TBL] [Abstract][Full Text] [Related]
15. Augmenting central arterial stiffness following eradication of HCV by direct acting antivirals in advanced fibrosis patients.
Cheng PN; Chen JY; Chiu YC; Chiu HC; Tsai LM
Sci Rep; 2019 Feb; 9(1):1426. PubMed ID: 30723238
[TBL] [Abstract][Full Text] [Related]
16. The impact of a successful treatment of hepatitis C virus on glyco-metabolic control in diabetic patients: a systematic review and meta-analysis.
Carnovale C; Pozzi M; Dassano A; D'Addio F; Gentili M; Magni C; Clementi E; Radice S; Fiorina P
Acta Diabetol; 2019 Mar; 56(3):341-354. PubMed ID: 30478781
[TBL] [Abstract][Full Text] [Related]
17. Liver function following hepatitis C virus eradication by direct acting antivirals in patients with liver cirrhosis: data from the PITER cohort.
Quaranta MG; Ferrigno L; Tata X; D'Angelo F; Coppola C; Ciancio A; Bruno SR; Loi M; Giorgini A; Margotti M; Cossiga V; Brancaccio G; Dallio M; De Siena M; Cannizzaro M; Cavalletto L; Massari M; Mazzitelli M; De Leo P; Laccabue D; Baiocchi L; Kondili LA
BMC Infect Dis; 2021 May; 21(1):413. PubMed ID: 33947337
[TBL] [Abstract][Full Text] [Related]
18. Decoupled Glucose and Lipid Metabolic Recovery after Viral Clearance in Direct-Acting Antiviral-Treated HCV Patients: A 3-Year Prospective Cohort Study.
Lee H; Chien RN; Pao LH; Kuo CJ; Huang PH; Chang ML
Cells; 2021 Oct; 10(11):. PubMed ID: 34831156
[TBL] [Abstract][Full Text] [Related]
19. Study of changes in lipid profile and insulin resistance in Egyptian patients with chronic hepatitis C genotype 4 in the era of DAAs.
El Sagheer G; Soliman E; Ahmad A; Hamdy L
Libyan J Med; 2018 Dec; 13(1):1435124. PubMed ID: 29451090
[TBL] [Abstract][Full Text] [Related]
20. Regression of liver fibrosis over a 24-week period after completing direct-acting antiviral therapy in patients with chronic hepatitis C receiving care within the national hepatitis C elimination program in Georgia: results of hepatology clinic HEPA experience.
Dolmazashvili E; Abutidze A; Chkhartishvili N; Karchava M; Sharvadze L; Tsertsvadze T
Eur J Gastroenterol Hepatol; 2017 Nov; 29(11):1223-1230. PubMed ID: 28857900
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]